Can castor oil improve tear film and ocular surface quality?

Phase 2

• Conditions: Eye - Diseases / disorders of the eye; Blepharitis

• Registration Number: ACTRN12618000856213
• Lead Sponsor: The University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-22
• Last Update Posted: 22 October 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Aged over 18 years
Clinical signs and symptoms of anterior blepharitis
Symmetry in signs and symptoms of both eyes at baseline
Crusting of the eyelashes and/or signs of meibomian gland dysfunction

Exclusion Criteria

Current topical use of eye drops other than occasional use of artificial tears
Current active infection
Abnormal eyelid architecture that prevents full eyelid closure during blinking
Use of systemic medications that are known to affect the lacrimal system (cause eye dryness)
Changed or planned change in systemic medication within 4 weeks of study commencement

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ipid layer grade change of greater than or equal to 1 grade on the Guillon grading scale, evaluated by interferometry using the Oculus Keratograph 5M[Baseline, 4 weeks after treatment commencement]

Secondary Outcome Measures

Name	Time	Method
Clinical blepharitis grade as assessed by slit lamp examination[Baseline, 4 weeks after treatment commencement];Non-invasive tear film stability as measured by the Oculus Keratograph 5M[Baseline, 4 weeks after treatment commencement];Discomfort symptoms (on the Ocular Surface Disease Index validated questionnaire)[Baseline, 4 weeks after treatment commencement];Bulbar hyperaemia as assessed objectively with the Oculus Keratograph 5M[Baseline, 4 weeks after treatment commencement]